<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">For patients who cannot tolerate or absorb enteric oseltamivir due to gastric stasis, malabsorption, or other gastrointestinal processes, intravenous peramivir may be an alternative [
 <xref ref-type="bibr" rid="CR99">99</xref>, 
 <xref ref-type="bibr" rid="CR100">100</xref>]; however, studies have not identified an advantage for intravenous peramivir in comparison with enteric oseltamivir [
 <xref ref-type="bibr" rid="CR101">101</xref>]. Notably, a randomized trial conducted in three influenza seasons found similar clinical outcomes between IV peramivir and enteric oseltamivir in hospitalized adult influenza patients [
 <xref ref-type="bibr" rid="CR102">102</xref>]; a separate trial did not identify significant additional clinical benefit of peramivir in combination with standard-of-care therapy (which often included an NAI) [
 <xref ref-type="bibr" rid="CR103">103</xref>]. A more recent, multicenter randomized controlled trial also found similar clinical benefit between enteric oseltamivir and intravenous peramivir in hospitalized influenza patients [
 <xref ref-type="bibr" rid="CR104">104</xref>].
</p>
